To examine the integration of PET/MRI imaging with liquid biopsy for a comprehensive understanding of tumor biology and to enhance clinical decision-making in cancer care, emphasizing its significance in improving patient outcomes.
The integration enhances early diagnosis, resolves spatial heterogeneity, and enables monitoring of treatment efficacy.
Current evidence supports the potential of this approach, though it is primarily from retrospective studies, highlighting challenges in technical standardization and algorithmic development.
Interpretation:
The fusion of PET/MRI and liquid biopsy could revolutionize cancer diagnostics and treatment by providing a more comprehensive view of tumor biology, ultimately improving patient care.
Limitations:
Challenges in technical standardization and algorithmic development for data integration.
Need for large-scale prospective validation of the integrated approach to ensure reliability and effectiveness.
Conclusion:
Advancements in artificial intelligence may help overcome existing challenges, particularly in standardization and data integration, paving the way for precision medicine in oncology.
